JP2025515485A - 眼の疾患を治療するための組成物及び方法 - Google Patents

眼の疾患を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2025515485A
JP2025515485A JP2024563560A JP2024563560A JP2025515485A JP 2025515485 A JP2025515485 A JP 2025515485A JP 2024563560 A JP2024563560 A JP 2024563560A JP 2024563560 A JP2024563560 A JP 2024563560A JP 2025515485 A JP2025515485 A JP 2025515485A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515485A5 (enExample
Inventor
イェドノック，テッド
テイラー，ロリ
グローヴァー，アニタ
フォン，ドナルド
Original Assignee
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アネクソン，インコーポレーテッド filed Critical アネクソン，インコーポレーテッド
Publication of JP2025515485A publication Critical patent/JP2025515485A/ja
Publication of JP2025515485A5 publication Critical patent/JP2025515485A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024563560A 2022-04-29 2023-04-28 眼の疾患を治療するための組成物及び方法 Pending JP2025515485A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336539P 2022-04-29 2022-04-29
US63/336,539 2022-04-29
PCT/US2023/066393 WO2023212719A1 (en) 2022-04-29 2023-04-28 Compositions and methods for treating ocular diseases

Publications (2)

Publication Number Publication Date
JP2025515485A true JP2025515485A (ja) 2025-05-15
JP2025515485A5 JP2025515485A5 (enExample) 2026-05-08

Family

ID=88519880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563560A Pending JP2025515485A (ja) 2022-04-29 2023-04-28 眼の疾患を治療するための組成物及び方法

Country Status (10)

Country Link
US (1) US20250313614A1 (enExample)
EP (1) EP4518896A4 (enExample)
JP (1) JP2025515485A (enExample)
KR (1) KR20250006238A (enExample)
CN (1) CN119136830A (enExample)
AU (1) AU2023262202A1 (enExample)
CA (1) CA3250843A1 (enExample)
IL (1) IL316218A (enExample)
MX (1) MX2024013326A (enExample)
WO (1) WO2023212719A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184235A1 (en) * 2024-02-28 2025-09-04 Onl Therapeutics, Inc. Methods and compositions for treating glaucoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
CN116782940A (zh) * 2020-12-04 2023-09-19 安尼艾克松股份有限公司 用于治疗眼部疾病的组合物和方法

Also Published As

Publication number Publication date
AU2023262202A1 (en) 2024-10-24
KR20250006238A (ko) 2025-01-10
US20250313614A1 (en) 2025-10-09
IL316218A (en) 2024-12-01
WO2023212719A1 (en) 2023-11-02
CN119136830A (zh) 2024-12-13
EP4518896A1 (en) 2025-03-12
EP4518896A4 (en) 2026-08-12
CA3250843A1 (en) 2023-11-02
MX2024013326A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
AU2007329759B2 (en) Compositions and methods for binding sphingosine-1-phosphate
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
US20240059765A1 (en) Compositions and methods for treating ocular diseases
MX2014004449A (es) Tratamiento de enfermedad ocular.
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
US20250313614A1 (en) Compositions and methods for treating ocular diseases
HK40121733A (en) Compositions and methods for treating ocular diseases
EA050212B1 (ru) Композиции и способы лечения болезней глаз
HK40101076A (en) Compositions and methods for treating ocular diseases
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241111

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241118

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20241111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260424